↓ Skip to main content

ENabling Reduction of Low‐grade Inflammation in SEniors Pilot Study: Concept, Rationale, and Design

Overview of attention for article published in Journal of the American Geriatrics Society, July 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

news
13 news outlets

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
121 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
ENabling Reduction of Low‐grade Inflammation in SEniors Pilot Study: Concept, Rationale, and Design
Published in
Journal of the American Geriatrics Society, July 2017
DOI 10.1111/jgs.14965
Pubmed ID
Authors

Todd M. Manini, Stephen D. Anton, Daniel P. Beavers, Jane A. Cauley, Mark A. Espeland, Roger A. Fielding, Stephen B. Kritchevsky, Christiaan Leeuwenburgh, Kristina H. Lewis, Christine Liu, Mary M. McDermott, Michael E. Miller, Russell P. Tracy, Jeremy D. Walston, Barbara Radziszewska, Jane Lu, Cindy Stowe, Samuel Wu, Anne B. Newman, Walter T. Ambrosius, Marco Pahor, ENRGISE Pilot study investigators

Abstract

To test two interventions to reduce interleukin (IL)-6 levels, an indicator of low-grade chronic inflammation and an independent risk factor for impaired mobility and slow walking speed in older adults. The ENabling Reduction of low-Grade Inflammation in SEniors (ENRGISE) Pilot Study was a multicenter, double-blind, placebo-controlled randomized pilot trial of two interventions to reduce IL-6 levels. Five university-based research centers. Target enrollment was 300 men and women aged 70 and older with an average plasma IL-6 level between 2.5 and 30 pg/mL measured twice at least 1 week apart. Participants had low to moderate physical function, defined as self-reported difficulty walking one-quarter of a mile or climbing a flight of stairs and usual walk speed of less than 1 m/s on a 4-m usual-pace walk. Participants were randomized to losartan, omega-3 fish oil (ω-3), combined losartan and ω-3, or placebo. Randomization was stratified depending on eligibility for each group. A titration schedule was implemented to reach a dose that was safe and effective for IL-6 reduction. Maximal doses were 100 mg/d for losartan and 2.8 g/d for ω-3. IL-6, walking speed over 400 m, physical function (Short Physical Performance Battery), other inflammatory markers, safety, tolerability, frailty domains, and maximal leg strength were measured. Results from the ENRGISE Pilot Study will provide recruitment yields, feasibility, medication tolerance and adherence, and preliminary data to help justify a sample size for a more definitive randomized trial. The ENRGISE Pilot Study will inform a larger subsequent trial that is expected to have important clinical and public health implications for the growing population of older adults with low-grade chronic inflammation and mobility limitations.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 121 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 121 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 18 15%
Researcher 17 14%
Student > Ph. D. Student 11 9%
Student > Doctoral Student 11 9%
Student > Bachelor 11 9%
Other 20 17%
Unknown 33 27%
Readers by discipline Count As %
Medicine and Dentistry 23 19%
Nursing and Health Professions 11 9%
Biochemistry, Genetics and Molecular Biology 9 7%
Sports and Recreations 8 7%
Psychology 5 4%
Other 20 17%
Unknown 45 37%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 97. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 September 2017.
All research outputs
#369,242
of 22,999,744 outputs
Outputs from Journal of the American Geriatrics Society
#350
of 7,476 outputs
Outputs of similar age
#8,837
of 315,944 outputs
Outputs of similar age from Journal of the American Geriatrics Society
#14
of 80 outputs
Altmetric has tracked 22,999,744 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,476 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 23.0. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,944 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 80 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.